4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has earned an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $28.90.

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald raised 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 target price on the stock in a research report on Monday, September 14th. Chardan Capital cut their price target on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, October 6th. The Goldman Sachs Group restated a “buy” rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Bank of America boosted their target price on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, September 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $12.87 on Tuesday. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics has a twelve month low of $6.96 and a twelve month high of $16.93. The business’s fifty day moving average is $13.97 and its 200-day moving average is $11.51. The company has a market cap of $710.94 million, a P/E ratio of -4.89 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. The company had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. Equities research analysts forecast that 4D Molecular Therapeutics will post -4.14 EPS for the current year.

Insider Buying and Selling

In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the completion of the sale, the insider owned 709,153 shares of the company’s stock, valued at approximately $9,162,256.76. The trade was a 7.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 134,570 shares of company stock worth $1,759,323 over the last three months. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Persistent Asset Partners Ltd bought a new stake in 4D Molecular Therapeutics during the second quarter worth about $1,936,000. Deutsche Bank AG acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $9,456,000. Bank of America Corp DE acquired a new position in 4D Molecular Therapeutics during the 2nd quarter worth approximately $14,905,000. Dimensional Fund Advisors LP grew its stake in shares of 4D Molecular Therapeutics by 77.3% during the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock worth $4,863,000 after buying an additional 227,982 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the first quarter worth $1,216,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.